GILD GILEAD SCIENCES, INC.

Price Chart

Executive Summary

Gilead Sciences (GILD) received an upgrade from Truist Securities on August 8, 2025, moving from Hold to Buy with a price target of $127, up from $108. The upgrade is part of a cluster of 14 firms taking action on GILD. Truist has a perfect 100% accuracy on 4 rated calls with an average return of 9.7%, placing it among top-tier firms. The broader consensus is strongly bullish: 31 of 39 analysts rate it Buy (79%), 8 Hold, 0 Sell. The mean price target is $158.36, the median $160.5, with a high of $180 and low of $123. Current price at $130.84 offers 21% upside to the mean target, though Truist's $127 target is below the current price. Over the past 30 days, earnings have seen mixed revisions: longer-term +1y EPS estimates saw 8 upward and 6 downward revisions, while current fiscal year estimates have 4 up and 12 down. Insider selling has been heavy, with multiple executives selling shares worth over $3M combined in the last two months. Short interest stands at 56.1%, indicating high bearish sentiment. Despite the upgrade, the negative signals from insiders and shorts suggest caution.

Impact Score

Consensus & Targets

The consensus among 39 analysts is strongly bullish: 11 Strong Buy, 20 Buy, 8 Hold, 0 Sell, 0 Strong Sell. That's 79% Buy-equivalent ratings, with no sell-side recommendations. The bullish consensus is a significant driver for the stock.

Current price $130.84. Mean PT $158.36, median $160.5, high $180, low $123. Implied upside to mean is 21%. Truist's PT of $127 sits at the low end of the range and is actually 3% below the current price, contrasting with the bullish consensus.

Recent Analyst Activity

Over the past 30 days, there have been 0 upgrades and 0 downgrades, indicating no recent rating momentum. EPS revision trends are mixed: for the current quarter (0q), 5 up and 6 down; for the next quarter (+1q), 3 up and 6 down; for the current fiscal year (0y), 4 up and 12 down; for the +1y period, 8 up and 6 down. Near-term estimates are being revised lower, while longer-term projections show slight upward momentum.

Firm Track Record — Truist Securities

Truist Securities accuracy: 55% on 3795 calls | avg return: 3.1%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Truist Securities has a 100% accuracy on 4 rated calls on GILD, with an average return of 9.7%, placing it in the top tier among covering firms. However, the small sample size (4) limits statistical significance. Other top performers include TD Cowen (100% on 2 calls, 16.2% avg return), Citigroup (100% on 2 calls, 8.3%), and UBS (100% on 3 calls, 11.5%). The worst-performing among those with sufficient data is Wells Fargo (67% on 6 calls, 7.9% avg return).

Earnings Estimates

Next earnings: May 7, 2026

Cross-Platform Signals

Insider trading shows heavy selling: executives sold over $3.5M in shares in the past two months, including CEO O'Day and CFO Dickinson. There are no congressional trades on record. Institutional activity is mixed: Norges Bank initiated a large new position ($2.6B) but also exited a previous position; Two Sigma initiated; Renaissance Technologies trimmed 49% of its position; Ariel Investments trimmed 40.7%. Short interest is elevated at 56.1%, suggesting significant bearish bets. The analyst upgrade diverges from the insider selling and high short interest.

Documents Analyzed

Report based on filing metadata.

US Market Status